Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
Authors
A. Michael Lincoff (ORCID: https://orcid.org/0000-0001-8175-2121)
Eran Leitersdorf (ORCID: https://orcid.org/0000-0001-8740-9068)
Brian J. Manning (ORCID: https://orcid.org/0000-0001-5770-6205)
Leslie Cho (ORCID: https://orcid.org/0000-0002-1190-1774)
Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
A. Michael Lincoff, Eran Leitersdorf, Brian J. Manning, Leslie Cho et al.
Citations
75 citations
Journal
American Heart Journal
Topics
Lipoproteins and Cardiovascular Health
Field-Weighted Citation Impact (FWCI)
150.48
article
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
A. Michael Lincoff, Eran Leitersdorf, Brian J. Manning, Leslie Cho, Stephen James Nicholls, Anastasia Lesogor, Plamen Kozlovski, Børge Grønne Nordestgaard, Sotirios Tsimikas, Jing Wang, Hui Cao, Michael J. Blaha, Ulf Landmesser, Steven E. Nissen
article en
75 citations
Abstract
No abstract available for this paper.
Publication Tag
American Heart JournalVol. 287
Institutions
University of Copenhagen (DK), Novartis (Switzerland) (CH), Cleveland Clinic (US), Johns Hopkins University (US), Hebrew University of Jerusalem (IL), Hadassah Medical Center (IL), University of California San Diego (US), Deutsches Herzzentrum der Charité (DE), Novartis (United States) (US), Australian Centre for Heart Health (AU), Monash University (AU)